Accès ouvert
2026
article
OpenAlex
Jiakun Mei, Xue Han⊗, Kai Zhang, Naijian Ge et autres
BACKGROUND & AIMS: First-line immuno-chemotherapy is standard for advanced biliary tract cancer (BTC), but outcomes vary substantially, necessitating longitudinal monitoring and treatment adaptation. We aimed to develop models that dynamically update survival predictions using evolving clinical data to support real-time prognostic stratification. …
cn
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Jiakun Mei, Kai Zhang, Ying Zhang, Zhen Li et autres
BACKGROUND & AIMS: Immunochemotherapy (IO-chemo) has become standard care for patients with unresectable intrahepatic cholangiocarcinoma (iCCA), but benefit of adding IO varies greatly among individuals. We sought to develop a system to identify patients most likely to benefit from this treatment based …
cn
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Jiakun Mei, Jian Lu, Kai Zhang, Ying Zhang et autres
1 Background: Immunochemotherapy (IO-chemo) has become the first-line standard care for patients with advanced intrahepatic cholangiocarcinoma (iCCA), but the incremental benefit of adding IO varies greatly among individuals, making it urgent to develop systems for identifying high-benefit populations based on individualized treatment …
cn, us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Tiancai Zhang, Dongqing Dou, Qi Liu, Dong Xu et autres
Intrahepatic cholangiocarcinoma (iCCA) is an aggressive malignancy characterized by profound molecular heterogeneity and poor prognosis. Programmed cell death (PCD) regulates tumor progression and shapes the tumor immune microenvironment (TME), yet the roles of distinct PCD subtypes in iCCA remain elusive. Here, we …
cn
(code pays fourni par la source)